ChroMedX Corp. announced the appointments of Dr. Richard Janeczko as Chief Commercial Officer (CCO) and Jessica Kuhn as Chief Operations Officer (COO). Dr. Janeczko and Ms. Kuhn's positions are effective immediately. Ms. Jessica Kuhn has worked in technology product development for over a decade. Jessica acted as COO at Kangaroo Group alongside CEO Lahav Gil where she managed operations and development on projects for key clientele until Kangaroo was sold in 2017. The board of directors now welcomes her as COO of ChroMedX. Dr. Janeczko brings over 25 years of experience in the in-vitro diagnostics industry having held executive roles in numerous diagnostic companies before he founded healthcare economic consulting firm DxEconomix Inc. in 2013. Richard joined the board of ChroMedX in December 2017 and has now joined the executive team as CCO leading the commercial strategy of the HemoPalm Handheld Blood Analyzer System. As Chief Commercial Officer Dr. Janeczko is responsible for the management of marketing and business development activities related to the development and positioning of the HemoPalm Handheld Blood Analyzer System. Dr. Janeczko's core focus is to optimize the market potential of the HemoPalm and ensure the Company's readiness for the completion of a high value transaction. This includes the alignment of the product development plan and technology roadmap with market needs as well as compatibility with critical care clinical management practices and cost-effectiveness goals. As CCO Richard will be corresponding with and assessing individual strategic players to determine how the HemoPalm specifically aligns with their market strategies to maximize the Company's value offering to existing product lines. In addition, Richard will be organizing relationships with clinical sites in order to run HemoPalm trials under various scenarios for both regulatory and market development purposes. Dr. Janeczko served as VP Emerging Markets and Technology at Luminex Corporation, as EVP Business Development and CSO at Tm Bioscience Inc., and as CEO of General Synthesis and Diagnostics. Ms. Kuhn has extensive experience managing projects in technology product development. She was formerly COO of Kangaroo group where she worked to implement systems and processes to improve and build stability in Kangaroo's operations, while managing development projects for key clients.